craft-sa-dev Home  

PMC:1584416 / 22432-22724 JSONTXT 5 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T3842 4-7 CC denotes and
T3843 8-14 NN denotes XpdTTD
T3845 14-15 HYPH denotes /
T3844 15-19 NN denotes  †XP
T3837 20-25 NNS denotes cells
T3846 25-26 . denotes .
T3847 26-248 sentence denotes Previously, using comparative immunohistochemistry, we and others have shown an up to 70% reduction of TFIIH levels in primary fibroblasts from patients with TTD compared with wt controls due to reduced stability [16,17].
T3848 27-37 RB denotes Previously
T3850 37-39 , denotes ,
T3851 39-44 VBG denotes using
T3852 45-56 JJ denotes comparative
T3853 57-77 NN denotes immunohistochemistry
T3854 77-79 , denotes ,
T3855 79-81 PRP denotes we
T3856 82-85 CC denotes and
T3857 86-92 NNS denotes others
T3858 93-97 VBP denotes have
T3849 98-103 VBN denotes shown
T3859 104-106 DT denotes an
T3861 107-109 IN denotes up
T3863 110-112 IN denotes to
T3862 113-115 CD denotes 70
T3864 115-116 NN denotes %
T3860 117-126 NN denotes reduction
T3865 127-129 IN denotes of
T3866 130-135 NN denotes TFIIH
T3867 136-142 NNS denotes levels
T3868 143-145 IN denotes in
T3869 146-153 JJ denotes primary
T3870 154-165 NNS denotes fibroblasts
T3871 166-170 IN denotes from
T3872 171-179 NNS denotes patients
T3873 180-184 IN denotes with
T3874 185-188 NN denotes TTD
T3875 189-197 VBN denotes compared
T3876 198-202 IN denotes with
T3877 203-205 NN denotes wt
T3878 206-214 NNS denotes controls
T3879 215-218 IN denotes due
T3880 219-221 IN denotes to
T3881 222-229 VBN denotes reduced
T3882 230-239 NN denotes stability
T3883 240-241 -LRB- denotes [
T3885 241-243 CD denotes 16
T3886 243-244 , denotes ,
T3884 244-246 CD denotes 17
T3887 246-247 -RRB- denotes ]
T3888 247-248 . denotes .
T3890 249-256 IN denotes Despite
T3892 257-271 NN denotes overexpression
T3893 272-274 IN denotes of
T3894 275-279 NN denotes mRNA
T3895 280-284 IN denotes from
T3896 285-288 DT denotes the
R2551 T3843 T3844 compound XpdTTD, †XP
R2553 T3845 T3844 punct /, †XP
R2554 T3848 T3849 advmod Previously,shown
R2555 T3850 T3849 punct ", ",shown
R2556 T3851 T3849 advcl using,shown
R2557 T3852 T3853 amod comparative,immunohistochemistry
R2558 T3853 T3851 dobj immunohistochemistry,using
R2559 T3854 T3849 punct ", ",shown
R2560 T3855 T3849 nsubj we,shown
R2561 T3856 T3855 cc and,we
R2562 T3857 T3855 conj others,we
R2563 T3858 T3849 aux have,shown
R2564 T3859 T3860 det an,reduction
R2565 T3860 T3849 dobj reduction,shown
R2566 T3861 T3862 quantmod up,70
R2567 T3862 T3864 nummod 70,%
R2568 T3863 T3862 quantmod to,70
R2569 T3864 T3860 compound %,reduction
R2570 T3865 T3860 prep of,reduction
R2571 T3866 T3867 compound TFIIH,levels
R2572 T3867 T3865 pobj levels,of
R2573 T3868 T3867 prep in,levels
R2574 T3869 T3870 amod primary,fibroblasts
R2575 T3870 T3868 pobj fibroblasts,in
R2576 T3871 T3870 prep from,fibroblasts
R2577 T3872 T3871 pobj patients,from
R2578 T3873 T3872 prep with,patients
R2579 T3874 T3873 pobj TTD,with
R2580 T3875 T3860 prep compared,reduction
R2581 T3876 T3875 prep with,compared
R2582 T3877 T3878 compound wt,controls
R2583 T3878 T3876 pobj controls,with
R2584 T3879 T3860 prep due,reduction
R2585 T3880 T3879 pcomp to,due
R2586 T3881 T3882 amod reduced,stability
R2587 T3882 T3879 pobj stability,due
R2588 T3883 T3884 punct [,17
R2589 T3884 T3849 parataxis 17,shown
R2590 T3885 T3884 nummod 16,17
R2591 T3886 T3884 punct ",",17
R2592 T3887 T3884 punct ],17
R2593 T3888 T3849 punct .,shown
R2595 T3892 T3890 pobj overexpression,Despite
R2596 T3893 T3892 prep of,overexpression
R2597 T3894 T3893 pobj mRNA,of
R2598 T3895 T3894 prep from,mRNA